Hideko Goto

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin?s lymphoma: in combination with the International Prognostic Index

Hideko Goto, Hisashi Tsurumi, Masao Takemura et al. · Journal of Cancer Research and Clinical Oncology · 2004 · 63 citations · Full text

Medicine, Immunology, Oncology +11

Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens

Naoe Goto, Hisashi Tsurumi, Hideko Goto et al. · Annals of Hematology · 2011 · 63 citations

Medicine, Hematology, Oncology +6

Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma

Takeshi Hara, Hisashi Tsurumi, Masao Takemura et al. · American Journal of Hematology · 2000 · 43 citations

Medicine, Immunology, Oncology +12

Late-Onset Neutropenia in Patients Treated with Rituximab for Non-Hodgkin's Lymphoma

Kenji Fukuno, Hisashi Tsurumi, Nobuhiro Ando et al. · International Journal of Hematology · 2006 · 43 citations

Medicine, Hematology, Immunology +8

R‐THP‐COP versus R‐CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open‐label, noninferiority phase 3 trial

Takeshi Hara, Takeshi Yoshikawa, Hideko Goto et al. · Hematological Oncology · 2018 · 37 citations

Medicine, Hematology, Oncology +14